; and (B) in compliance with the requirements of this Act. (8) Special rule If cannabis, or any component thereof, is placed in a schedule other than schedule I, the Attorney General may, as the Attorney General determines appropriate— (A) treat the reference to subsection (a) in paragraph (2)(C) of this subsection as a reference to subsection (d); and (B) treat the references to schedule I in paragraph (3) as references to the appropriate schedule. (9) Definition In this subsection, the term legitimate research purposes has the meaning given to such term for purposes of subsection (a)(1). . (b) Transitional provisions (1) Current registrants Notwithstanding paragraph (1) of section 303(k) of the Controlled Substances Act, as added by subsection (a), any manufacturer that is registered under section 303(a) of the Controlled Substances Act ( 21 U.S.C. 823(a) ) to manufacture cannabis as of the date of enactment of this Act shall not be required to obtain a separate registration under such section 303(k) for the 1-year period following the date of enactment of this Act. (2) Pending applications The Attorney General of the United States shall grant or deny, in accordance with section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ), as amended by subsection (a), each application to manufacture cannabis to supply researchers in the United States that was submitted— (A) pursuant to the policy statement entitled Applications To Become Registered Under the Controlled Substances Act To Manufacture Marijuana To Supply Researcher in the United States published by the Drug Enforcement Administration in the Federal Register on August 12, 2016 (81 Fed. Reg. 53846)